Arsenic Trioxide During Consolidation for Patients with Previously Untreated Low/Intermediate Risk Acute Promyelocytic Leukaemia May Eliminate the Need for Maintenance Therapy

A total of 105 patients (age ≥ 18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight patients who were polymerase chain reaction (PCR) negative for PML...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Coutre, Steven E., Othus, Megan, Powell, Bayard, Willman, Cheryl L., Stock, Wendy, Paietta, Elisabeth, Levitan, Denise, Wetzler, Meir, Attar, Eyal C., Altman, Jessica K., Gore, Steven D., Maher, Tracy, Kopecky, Kenneth J., Tallman, Martin S., Larson, Richard A., Appelbaum, Frederick R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064464/
https://ncbi.nlm.nih.gov/pubmed/24528179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12775
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak